Psychedelics field looks ahead after FDA advisers' rejection.
Science (New York, N.Y.) June 14, 2024 DOI: 10.1126/science.adr0286 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary or analysis Peer reviewed |
|---|---|
| Keywords | Psychedelic-medicine MDMA-Therapy Clinical-trials Drug-regulation Mental-health-treatment |
| Citations | 3 |
| Key points | Argues that researchers are analyzing the FDA's rejection of MDMA-assisted PTSD therapy to identify methodological shortcomings and improve future psychedelic studies. |
Abstract
Reeling from negative vote on MDMA-assisted PTSD therapy, researchers seek lessons for future studies.